InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Researchers found that inhibiting the enzyme TYK2 may reduce the harmful accumulation of tau protein in Alzheimer’s disease, ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...

TYK2 enzyme changes tau protein from a protective role to a harmful one, contributing to Alzheimer’s disease progression.

Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital and collaborating institutions discovered that the enzyme ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...

The JAK3/TYK2 inhibitor ritlecitinib received FDA approval for this indication in 2023; brepocitinib, a TYK2/JAK1 inhibitor, ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of ...